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Abstract
Background: The management of patients with surgically incurable bowel cancer at presentation
is controversial. The aims of treatment are to optimise quality of life and prolong survival. It has
been believed that the most effective palliation is achieved by resection of the primary cancer in
order to pre-empt future complications. This study reviews and compares the outcomes of
patients with incurable bowel cancer managed by resection and non-resection strategies over a 7-
year period in a single District General Hospital.
Patients and methods: All patients with surgically incurable bowel cancer at presentation were
identified from the prospectively collected local ACPGBI database. Survival, using Kaplan-Meier
method and log-rank test, was compared between patients managed by resection of the primary,
non-resectional intervention (surgery, stent & oncological treatments) and those managed with
supportive care only. The primary endpoint of the study was survival on an intention to treat basis,
compared using Kaplan-Meier and log-rank tests.
Results: Of 646 consecutive newly diagnosed bowel cancer patients over a 7 year period 154 cases
(24%) were deemed surgically incurable at presentation. Of these surgical resection was carried
out in 45 patients (29%), non-resectional intervention was followed in 52 patients (34%) and
supportive treatment alone in 57 patients (37%). Median survival of each group was as follows:
resected patients 11 months (I.Q range 3–18 months), non-resectional intervention 7 months (I.Q
range 2–15 months) and supportive care alone 2 months (I.Q range 1–8 months). Only one patient
(2%) managed by non-resectional intervention required later surgery to treat primary tumour
related complications. Survival was not significantly different between resection and non-resection
treatments. The overall operative mortality for the resection group was 16% (7/45 cases), with an
elective mortality of 14% (4/28 cases) and emergency mortality 18% (3/17 cases).
Conclusion: In an unselected bowel cancer population surgical resection of the primary tumour
in patients presenting with incurable disease does not improve survival and is associated with a high
risk of post-operative mortality.
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Colorectal cancer (CRC) is one of the most common
malignancies in the Western world. In the UK approxi-
mately 34000 patients have newly diagnosed colorectal
cancer each year[1]. Between 20–30% are found to have
synchronous distant metastases at the time of diagnosis
[2,3]. A small, select group will be suitable for resection of
hepatic metastases whereas the remaining majority are
deemed surgically incurable. The aim of treatment in the
majority of patients with advanced disease is palliation
with a view to optimise quality of life (QoL) and survival
time[4].
Patients diagnosed with Stage IV disease CRC present a
common clinical dilemma. It has been recommended that
optimal palliation can be achieved by resection of the pri-
mary, in order to pre-empt potential complications such
as obstruction, perforation or haemorrhage, and possibly
prolong survival [5,6]. However surgery, even in a non-
urgent situation, carries significant risks of mortality and
many patients with stage IV disease may die from progres-
sive systemic disease before the development of any pri-
mary tumour specific complication [7,8].
The aim of this retrospective study is to review the impact
of non-operative management of advanced CRC in an
unselected, consecutive series of patients presenting with
newly diagnosed disease. It reviews and compares the out-
comes of patients with advanced bowel cancer treated
with different treatment strategies, in a single colorectal
unit, over a 7-year period.
Patients and methods
Patients diagnosed with primary CRC between January
1999 and April 2006 were identified from the prospec-
tively collected information held in a local copy of the
Association of Coloproctology of Great Britain and Ire-
land colorectal cancer database. All patients underwent
colonic imaging (Barium enema or colonoscopy), and
staging with Computerised Tomography of the abdomen
and chest x-ray. Patients diagnosed with rectal carcinoma,
who were otherwise fit for surgery, also underwent Mag-
netic Resonance Imaging of the pelvis. Data collected
included demographic data, ASA score of operated
patients, stoma rates in operated patients and the indica-
tions for surgery in emergency patients. Patients deemed
surgically incurable at presentation were studied. Patients
with metastatic liver disease in whom curative treatment
was carried out (primary tumour and hepatic resection)
were excluded in this study.
The management plan for all patients, other than those
treated by emergency surgery, was agreed at the weekly
multi-disciplinary team meeting. The three treatment
options for discussion with the patient were: resection of
the primary lesion (resection group), non-resectional
treatment which included non-resectional surgery, the use
of self-expandable metallic stent and oncological treat-
ment alone (non-resection group) and patients receiving
symptomatic treatment only (supportive group). Advice
regarding surgical resection versus non-resection treat-
ment was based on two factors: presence of symptoms
(bleeding, perforation or obstruction), and fitness for sur-
gery. Those patients who were unfit for any active inter-
vention or who presented with terminal disease were
managed with supportive care. The study end point was
survival on an intention to treat basis. Kaplan-Meier
method and log-rank test were used to compare survival
between the sub-groups and Mann-Whitney U test used to
compare demographic data.
Results
A total of 646 consecutive newly diagnosed colorectal can-
cer patients were identified from the database during the
study period, 166 (26%) of whom were identified as stage
IV at presentation. Of the patients with stage IV disease 12
(7%) had liver metastases at presentation and underwent
potentially curative liver resection, so are excluded from
further analysis. 154 (93%) of stage IV patients were diag-
nosed with advanced, surgically incurable disease at pres-
entation, based on clinical examination and CT scan
findings. Forty-five patients (29%) had a surgical resec-
tion of the primary tumour, fifty-two patients (34%) had
active non-resectional treatment and fifty-seven patients
(37%) received supportive care alone.
In patients with stage IV disease, 145 have died during the
study period with an overall median survival time of 5
months (interquartile range 1–14 months). 2 patients
treated with resection are alive at 16 and 17 months post
resection, 5 patients treated with chemotherapy are alive
at 11, 15, 23, 28 and 29 months post diagnosis and 2
patients managed with supportive care alone are alive at 9
and 17 months. Overall follow up is as follows: 145
patients were followed until death and the remaining 9
patients for a median of 17 months (range 11–29
months). The age and median survival by treatment
modality utilised is summarised in table 1.
Patients treated by resection of the primary had the long-
est survival but this was not significantly longer than those
treated by active, non-resectional intervention (p =
0.2056) but was significantly greater than the group
treated with supportive care alone (p < 0.0001), Kaplan-
Meier curve figure 1. The median age of patients undergo-
ing resection was significantly lower than those treated
with supportive care (p = 0.026) but not different from
those offered active non-resectional treatment (p =
0.575). Of those patients undergoing resection, 28 were
performed electively and 17 as an emergency (12 forPage 2 of 7
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Table 1: Survival by treatment modality
Median Age (range) Number of cases Median survival 
(months)
Interquartile range 
(months)
Log rank p value 
against resection
Surgical resection 
of primary
72
(26–90)
45 11 3–18 -
Non-resection 
intervention
70
(44–93)
52 7 2–15 p = 0.2056
Supportive Care 79
(38–95)
57 2 1–8 p = < 0.0001
Survival by treatment modalitiesFigure 1
Survival by treatment modalities.
World Journal of Surgical Oncology 2009, 7:28 http://www.wjso.com/content/7/1/28bowel obstruction and 5 for faecal peritonitis). No differ-
ence in survival was observed between patients operated
electively and those having emergency resection (median
survival elective 12 months, IQ range 3–18, versus emer-
gency resection median survival 10 months, IQ range 1–
18, log-rank p = 0.95). Of those patients having elective
resection 71% were ASA grade I or II. Of those patients
having emergency resection 29% were ASA grade I or II.
Stoma rates were 32% (9/28) in elective cases and 53%
(9/17) in the emergency setting. The operative mortality
in patients undergoing elective resection was 14% (4/28)
patients and 18% (3/17) in patients having an emergency
resection. No difference in age or survival was seen when
elective and emergency resections were compared.
Non-resection intervention treatments included non-
resection surgery (defunctioning stoma/bypass), chemo-
therapy, radiotherapy and stent. Table 2 summarises the
number of cases, median age and survival for each modal-
ity. The operative mortality for non-resection surgery,
stoma formation or bypass, was 36% (5/14). Of the 52
patients initially treated without resection only 1 patient
underwent abdominal surgery prior to death – faecal
diversion 47 months following diagnosis and treatment
with chemotherapy. Two further patients had radio-
graphic evidence of bowel obstruction, at 6 and 18
months post diagnosis, but neither underwent surgery
prior to death. 9 patients required blood transfusion to
treat symptomatic anaemia (1 patient required 5 admis-
sions for transfusion, 2 patients required 2 admissions
and 6 patients required a single admission).
Discussion
The management of patients with stage IV CRC with unre-
sectable secondary disease remains challenging. Individ-
ual treatment needs to be tailored to optimise QoL and
survival taking into account the side effects and risks of
any active intervention. In patients that present requiring
emergency surgery, due to perforation or bleeding, the
decision is usually, although by no means always,
straightforward. However in those patients presenting
with non-distressing symptoms, does resection of the pri-
mary tumour offer a survival benefit and does resection
prevent the onset of symptoms due to tumour complica-
tions?
This non-case-matched study has compared the survival
of patients treated with resection of their primary against
non-resection intervention and supportive care on an
intention to treat basis. It has found that patients who
undergo resection of their primary disease have the long-
est survival, however, this was not significantly better than
those patients having active non-surgical treatment (p =
0.21). Patients treated with supportive treatment alone
only were observed to have significantly worse survival
than those treated by primary resection and non-resection
intervention (p < 0.001).
Recommendations on management of elective cases in
this series were made to patients based on multi-discipli-
nary team discussion that would have been guided by
patient symptoms and fitness, metastatic burden of dis-
ease and patient choice. Patients undergoing surgery were
either symptomatic from their disease or physiologically
fitter than those patients treated with non-resectional
measures, confirmed by 71% of elective surgery patients
having an ASA status of I or II and a median age of 72. The
elective operative mortality of 14% is high but given the
small number of patients in this series is in keeping with
the figure of 12% reported in the ACPGBI national
audit[9]. This level of postoperative mortality is an impor-
tant consideration when counselling patients for surgery
with stage IV disease.
In this series patients managed with supportive care only
experienced poor survival, the median being 2 months
and 18% (10 of 57 cases) of patients surviving less than 1
month from diagnosis. This self selected group of patients
treated with supportive care alone were those with very
Table 2: Summary of non-resectional intervention
Median Age (range) Number of cases Median survival (months) Interquartile range (months)
Non-resectional surgery 71
(44–87)
14 2 0–7
Chemotherapy alone 65
(49–75)
22 9 3–20
Radiotherapy 84
(66–93)
4 2 1–10
Stent 80
(57–92)
12 3 1–8Page 4 of 7
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undergo any from of anti-cancer treatment.
During the course of this series there have been several
changes in the management of stage IV CRC both in pal-
liative treatments and an increased role for potentially
curative hepatic resection. The number of patients consid-
ered suitable to undergo liver resection has increased as
new surgical therapies have been introduced[10]. In addi-
tion new chemotherapeutic agents have been employed
that have increased the feasibility of curative hepatic resec-
tion and significantly improved median survival for
patients with surgically incurable CRC[11]. Therefore it is
likely that some of the patients in this series and previous
reported series would today be candidates for more
aggressive liver surgery or use of newer chemotherapy reg-
imens that may improve the survival of both non-resec-
tion and resection treatment groups in this series.
One of the concerns in managing patients with surgically
incurable CRC without resection of the primary tumour is
the risk of the patient presenting acutely with obstruction,
bleeding or perforation either at the time of diagnosis or
subsequently. In this series only 1 patient (2%) patient
underwent surgery following an initial decision not to
resect the primary tumour. This was for bowel obstruction
not manageable by a stent. However a further 2 patients
(4%) had radiographic bowel obstruction that was man-
aged without surgery and 9 (17%) required blood transfu-
sion to treat anaemia.
For patients presenting with malignant large bowel
obstruction there is an increased trend in the use of self
expandable metallic stents (SEMS). A recent systematic
review examined the role of SEMS in this situation and
showed successful palliation in 90% of 336 reported cases
with technical failure reported in 8% of cases and perfora-
tion in 4% [12]. In this series the technique of stenting
was introduced and developed in the unit during the
study period and in the future may reduce the need for
emergency surgical intervention and stoma formation in
patients presenting with malignant large bowel obstruc-
tion.
Survival in metastatic CRC treated by resection and non-
resection strategies are unlikely to be compared in a ran-
domised control trial. The survival results of seven recent
studies are summarised in table 3. Whether resection of
the primary tumour affords a survival advantage is con-
tentious in theses series. Some previous studies have
shown a survival benefit from resection of the primary
[13-15] although in each of these series the non-resection
group appears to include patients who were managed
with supportive care alone, which may have biased the
results in favour of resection, which was a factor in our
decision to divide management strategies employed, in
Table 3: Comparison of survival of patients treated with resection and non-resection
Author Resection Non-resection p value
Number of patients Median survival 
(months)
Number of patients Median survival 
(months)
*Scoggins CR et al[17] 66 14.5 23
(22/23 received chemo)
16.6 0.59
*Ruo L et al[13] 127 16 103
86/103 received chemo)
9 < 0.001
*Tebutt NC et al[16] 280 14 82
all chemo
8.2 0.08 #
*Michel P et al[18] 31 21 23
(all chemo)
14 0.718
*Cook AD et al[14] 17658 Colon 11
Rectum 16
9096 Colon 2
Rectum 6
Chemo use not available
< 0.001
**Benoist S et al[19] 32 23 27
(all chemo)
22 0.753
*Konyalian et al[15] 62 12 47
(28/47 chemo)
4.6 < 0.0001
* non-case matched studies, ** case matched studies, # on multi-variate analysisPage 5 of 7
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if the survival of patients undergoing resection of their pri-
mary is compared with a combined group of patients
managed with non-resectional intervention and support-
ive care a survival benefit is observed from resecting the
primary (median 11 (IQ range 3–18) versus 3 months (IQ
range 1–10 months), p = 0.006)
There are other potential confounding factors in some
studies where the results favour resection. For example,
patients treated by resection were found to have a signifi-
cantly lower burden of disease in one study[13], and the
impact of case selection was not recorded in the oth-
ers[14,15]. Tebutt et al, have also showed improved sur-
vival in patients treated by resection against non-resection
although this was not significant on multi-variate analysis
(p = 0.08) although peritoneal disease, performance sta-
tus, alkaline phosphotase and albumin were[16]. The
remaining three studies have failed to show a survival
benefit from either strategy [17-19].
Palliative chemotherapy is the only treatment modality
which has been shown to improve survival of patients
with surgically incurable disease[20]. Therefore it has
been previously advocated that asymptomatic patients
with surgically incurable disease should proceed direct to
chemotherapy without resection of their primary tumour.
The rationale behind this treatment strategy relates to the
fact that patients are more likely to die of disease progres-
sion than any tumour specific complication and operative
intervention will delay commencement of chemotherapy
whilst post-operative recovery occurs [7,8,19,21].
Quality of life is of paramount importance to patients
with advanced CRC and although multidisciplinary teams
would consider this in tailoring individual treatment, the
lack of prospectively collected QoL data, like in other sim-
ilar studies, remains a limitation in this study.
Conclusion
This non-case-matched study has shown a high risk of in-
hospital mortality, with no significant survival benefit
from resection of the primary, in stage IV CRC, when com-
pared with other interventional, non-resection, treatment
modalities. Non-resection strategies should be offered as
part of the process of informed consent, for patients with
stage IV colorectal cancer, as survival is comparable to that
of resection and without the burden of a stoma. Further
studies are required to assess the impact of advances in
surgical oncology on QoL and survival in stage IV colorec-
tal cancer.
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